Dongha Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dongha Kim has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hye Jin Nam
Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea; Department of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon 34113, Republic of Korea
2 shared publications - Sung Hee Baek
Creative Research Initiatives Center for Epigenetic Code and Diseases, School of Biological Sciences, Seoul National University, Seoul 08826, Republic of Korea
2 shared publications Amen Shamim
Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon, 16419, South Korea
1 shared publication- Hijai Regina Shin
Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Hong Nam Kim
Division of Bio‐Medical Science & Technology KIST School Korea University of Science and Technology (UST) Seoul Republic of Korea
1 shared publication - Hyejin Ahn
Creative Research Initiatives Center for Epigenetic Code and Diseases, Department of Biological Sciences, Seoul National University, Seoul, 08826, South Korea
1 shared publication
Latest Publications
- Open Access
- 14 April 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (8) , 2174-2195
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Transcription factors, pivotal in gene expression regulation, are essential in cancer progression. Their function is meticulously regulated by post‐translational modifications, including ubiquitination. This process, which marks proteins for degradation, can either enhance or inhibit the function of transcription factors, contingent on the context. In cancers, dysregulated ubiquitination of transcription factors contributes to the hallmark of uncontrolled growth and survival of tumors. For example, tumor suppressors such as p53 might be degraded prematurely due to abnormal ubiquitination, causing genomic instability. On the other hand, oncogenic transcription factors may gain stability via ubiquitination, thus facilitating tumorigenesis. Targeting the ubiquitin–proteasome system (UPS) therefore could be a viable therapeutic approach in cancer. Emerging treatments aim to block the ubiquitination of oncogenic transcription factors or to stabilize tumor suppressors. This review underscores the critical impact of transcription factor‐altered ubiquitination on cancer progression. Additionally, it outlines innovative therapeutic approaches that involve inhibitors or drugs directed at specific ubiquitin E3 ligases and deubiquitinases (DUBs) that regulate transcription factor activity.
- 14 April 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (8) , 2174-2195
Open AccessUbiquitination of transcription factors in cancer: unveiling therapeutic potential
Transcription factors, pivotal in gene expression regulation, are essential in cancer progression. Their function is meticulously regulated by post‐translational modifications, including ubiquitination. This process, which marks proteins for degradation, can either enhance or inhibit the function of transcription factors, contingent on the context. In cancers, dysregulated ubiquitination of transcription factors contributes to the hallmark of uncontrolled growth and survival of tumors. For example, tumor suppressors such as p53 might be degraded prematurely due to abnormal ubiquitination, causing genomic instability. On the other hand, oncogenic transcription factors may gain stability via ubiquitination, thus facilitating tumorigenesis. Targeting the ubiquitin–proteasome system (UPS) therefore could be a viable therapeutic approach in cancer. Emerging treatments aim to block the ubiquitination of oncogenic transcription factors or to stabilize tumor suppressors. This review underscores the critical impact of transcription factor‐altered ubiquitination on cancer progression. Additionally, it outlines innovative therapeutic approaches that involve inhibitors or drugs directed at specific ubiquitin E3 ligases and deubiquitinases (DUBs) that regulate transcription factor activity.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (6) , 404-405
LOXL1-AS1/miR-761/PTEN as a Novel Signaling Pathway in Myocardial Ischemia and Reperfusion Injury (MIRI): Epigenetic Regulation by Long Non-Coding RNA (LncRNA) in MIRI
Korean Circulation Journal 대한심장학회지 순환기 Kim D. Korean Circ J. 2023 May;53:e35. https://doi.org/10.4070/kcj.2023.0055
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (6) , 404-405
Open AccessLOXL1-AS1/miR-761/PTEN as a Novel Signaling Pathway in Myocardial Ischemia and Reperfusion Injury (MIRI): Epigenetic Regulation by Long Non-Coding RNA (LncRNA) in MIRI
Korean Circulation Journal 대한심장학회지 순환기 Kim D. Korean Circ J. 2023 May;53:e35. https://doi.org/10.4070/kcj.2023.0055
- Open Access
- 29 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8412
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer patients with BRCA mutations. PARP inhibitors also exhibit positive results even in patients without homologous recombination (HR) deficiency. Therapeutic effects were successfully achieved; however, the development of resistance was unavoidable. Approximately 40–70% of patients are likely to develop resistance. Here, we describe the mechanisms of action of PARP inhibitors, the causes of resistance, and the various efforts to overcome resistance. Particularly, we determined the survival probability of cancer patients according to the expression patterns of genes associated with HR restoration, which are critical for the development of PARP inhibitor resistance. Furthermore, we discuss the innovative attempts to degrade PARP proteins by chemically modifying PARP inhibitors. These efforts would enhance the efficacy of PARP inhibitors or expand the scope of their usage.
- 29 July 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8412
Open AccessPARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer patients with BRCA mutations. PARP inhibitors also exhibit positive results even in patients without homologous recombination (HR) deficiency. Therapeutic effects were successfully achieved; however, the development of resistance was unavoidable. Approximately 40–70% of patients are likely to develop resistance. Here, we describe the mechanisms of action of PARP inhibitors, the causes of resistance, and the various efforts to overcome resistance. Particularly, we determined the survival probability of cancer patients according to the expression patterns of genes associated with HR restoration, which are critical for the development of PARP inhibitor resistance. Furthermore, we discuss the innovative attempts to degrade PARP proteins by chemically modifying PARP inhibitors. These efforts would enhance the efficacy of PARP inhibitors or expand the scope of their usage.
- Open Access
- 8 December 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Pontin arginine methylation by CARM1 is crucial for epigenetic regulation of autophagy
Autophagy is a catabolic process through which cytoplasmic components are degraded and recycled in response to various stresses including starvation. Recently, transcriptional and epigenetic regulations of autophagy have emerged as essential mechanisms for maintaining homeostasis. Here, we identify that coactivator-associated arginine methyltransferase 1 (CARM1) methylates Pontin chromatin-remodeling factor under glucose starvation, and methylated Pontin binds Forkhead Box O 3a (FOXO3a). Genome-wide analyses and biochemical studies reveal that methylated Pontin functions as a platform for recruiting Tip60 histone acetyltransferase with increased H4 acetylation and subsequent activation of autophagy genes regulated by FOXO3a. Surprisingly, CARM1-Pontin-FOXO3a signaling axis can work in the distal regions and activate autophagy genes through enhancer activation. Together, our findings provide a signaling axis of CARM1-Pontin-FOXO3a and further expand the role of CARM1 in nuclear regulation of autophagy.
- 8 December 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Open AccessPontin arginine methylation by CARM1 is crucial for epigenetic regulation of autophagy
Autophagy is a catabolic process through which cytoplasmic components are degraded and recycled in response to various stresses including starvation. Recently, transcriptional and epigenetic regulations of autophagy have emerged as essential mechanisms for maintaining homeostasis. Here, we identify that coactivator-associated arginine methyltransferase 1 (CARM1) methylates Pontin chromatin-remodeling factor under glucose starvation, and methylated Pontin binds Forkhead Box O 3a (FOXO3a). Genome-wide analyses and biochemical studies reveal that methylated Pontin functions as a platform for recruiting Tip60 histone acetyltransferase with increased H4 acetylation and subsequent activation of autophagy genes regulated by FOXO3a. Surprisingly, CARM1-Pontin-FOXO3a signaling axis can work in the distal regions and activate autophagy genes through enhancer activation. Together, our findings provide a signaling axis of CARM1-Pontin-FOXO3a and further expand the role of CARM1 in nuclear regulation of autophagy.
- Open Access
- 17 November 2020
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 5 (1) , 1-3
GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
- 17 November 2020
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 5 (1) , 1-3
Open AccessGSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro